Consolidated Entities and Acquisitions - Entasis Therapeutics Holdings, Inc. (Details) $ / shares in Units, $ in Thousands			3 Months Ended					9 Months Ended
	Jul. 11, 2022 USD ($)	Feb. 17, 2022 USD ($) $ / shares	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($) $ / shares shares	Sep. 30, 2020 USD ($) $ / shares shares	Jun. 30, 2020 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) Director	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Subsidiary or Equity Method Investee [Line Items]
Payments to acquire equity securities					$ 20,000
Total debt			$ 549,704					$ 549,704		$ 433,484
Remeasurement loss								7,700
Net loss attributable to Innoviva stockholders			265,523	$ 72,438				$ 282,235	$ 255,509
Entasis Therapeutics Holdings Inc
Subsidiary or Equity Method Investee [Line Items]
Number of shares to be purchased under the securities purchase agreement | shares							14,000,000
Number of investee's board members which may be designated by the Company | Director								2
Payment towards convertible promissory note	$ 0
Net loss attributable to Innoviva stockholders			2,700					$ 13,600
Measurement period adjustments for change in value of goodwill			(2,300)
Measurement period adjustments for change in estimated purchase price			(1,400)
Measurement period adjustments for change in value of noncontrolling interests			1,700
Measurement period adjustments for change in value of intangible assets			$ 2,500
Entasis Therapeutics Holdings Inc | Consolidated Investees [Member]
Subsidiary or Equity Method Investee [Line Items]
Equity method investment ownership percentage		59.90%
Entasis Therapeutics Holdings Inc | Securities Purchase Agreement | Convertible Promissory Note
Subsidiary or Equity Method Investee [Line Items]
Total debt		$ 15,000
Debt instrument maturity date		Aug. 18, 2022
Debt Instrument, annual interest rate		0.59%
Conversion price (dollars per share) | $ / shares		$ 1.48
Entasis Therapeutics Holdings Inc | Common stock
Subsidiary or Equity Method Investee [Line Items]
Number of shares to be purchased under the securities purchase agreement | shares						4,672,897
Fair value of equity securities		$ 64,500
Entasis Therapeutics Holdings Inc | Common stock | Innoviva Strategic Opportunities, LLC
Subsidiary or Equity Method Investee [Line Items]
Number of shares to be purchased under the securities purchase agreement | shares					10,000,000
Entasis Therapeutics Holdings Inc | Warrants
Subsidiary or Equity Method Investee [Line Items]
Number of warrants purchased under the securities purchase agreement | shares						4,672,897	14,000,000
Fair value of equity securities		$ 31,400
Entasis Therapeutics Holdings Inc | Warrants | Innoviva Strategic Opportunities, LLC
Subsidiary or Equity Method Investee [Line Items]
Number of shares to be purchased under the securities purchase agreement | shares					10,000,000
Entasis Therapeutics Holdings Inc | Common stock and warrants
Subsidiary or Equity Method Investee [Line Items]
Payments to acquire equity securities						$ 12,500	$ 35,000
Entasis Therapeutics Holdings Inc | Warrants acquired in second quarter of 2021
Subsidiary or Equity Method Investee [Line Items]
Exercise price of warrants | $ / shares					$ 2.00
Entasis Therapeutics Holdings Inc | Warrants acquired in third quarter of 2020
Subsidiary or Equity Method Investee [Line Items]
Exercise price of warrants | $ / shares						$ 2.675
Entasis Therapeutics Holdings Inc | Warrants acquired in second quarter of 2020
Subsidiary or Equity Method Investee [Line Items]
Exercise price of warrants | $ / shares							$ 2.50
Term of warrants			5 years					5 years